Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
bankruptcy, buy, Chardan, custodian, ESPP, HQ, nominal, payroll, refundable, resell, SAR, successor
Removed:
pro, underwriting
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Non-employee Director Compensation Policy
- 10.2 David Epstein Consulting Agreement
- 10.3 Severance Agreement Between the Company and Deborah Knobelman
- 10.4 Severance Agreement Between the Company and Philip Lee
- 10.5 Severance Agreement Between the Company and Timothy Lu
- 10.6 2022 Inducement Plan
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
Related press release
SNTI similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Senti Biosciences, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Timothy Lu, M.D., Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.
Date: November 10, 2022 | By: | /s/ Timothy Lu, M.D., Ph.D. | |||||||||
Timothy Lu, M.D., Ph.D. | |||||||||||
Chief Executive Officer | |||||||||||
(Principal Executive Officer) |